Amanote Research
Register
Sign In
Ponatinib Suppresses the Development of Myeloid and Lymphoid Malignancies Associated With FGFR1 Abnormalities
Leukemia
- United Kingdom
doi 10.1038/leu.2012.188
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Date
July 11, 2012
Authors
M Ren
H Qin
R Ren
J K Cowell
Publisher
Springer Science and Business Media LLC
Related search
Del(6q) Abnormalities in Lymphoid Malignancies
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer Research
Oncology
Genetics
Hematology
FGFR1 -Associated Myeloid Neoplasm With Increased Mast Cells
British Journal of Haematology
Hematology
EZH2 Abnormalities in Lymphoid Malignancies: Underlying Mechanisms and Therapeutic Implications
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Susceptibility Loci Associated With Specific and Shared Subtypes of Lymphoid Malignancies
PLoS Genetics
Evolution
Ecology
Genetics
Molecular Biology
Cancer Research
Systematics
Behavior
Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells
Frontiers in Oncology
Cancer Research
Oncology
Eruptive Melanocytic Nevi Associated With Ponatinib
JAAD Case Reports
Dermatology
CDK6 and P16INK4a in Lymphoid Malignancies
Oncotarget
Oncology
Rechallenge of Ponatinib in Chronic Myeloid Leukaemia After Hepatotoxicity
Hong Kong Medical Journal
Medicine
Novel Immunotherapies in Lymphoid Malignancies
Nature Reviews Clinical Oncology
Oncology